Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
November 07, 2024 16:02 ET
|
Nkarta, Inc.
First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2 expected to initiate by year-end 2024...
Nkarta to Participate in Upcoming Investor Conference
September 03, 2024 16:01 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
August 13, 2024 21:03 ET
|
Nkarta, Inc.
Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitisPreliminary clinical...
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
August 13, 2024 16:01 ET
|
Nkarta, Inc.
Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitisPreliminary clinical...
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
July 24, 2024 06:00 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that...
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
July 16, 2024 06:01 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced...
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
June 27, 2024 06:00 ET
|
Nkarta, Inc.
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for...
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
June 13, 2024 16:01 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies today...
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
May 09, 2024 16:01 ET
|
Nkarta, Inc.
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, 2024, including cash, cash...
Nkarta to Participate in Upcoming Investor Conferences
April 03, 2024 16:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...